Screener
BridgeBio Pharma BBIO Short-Term Investments
Short-Term Investments at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $879,891 | $570,119 |
| Marketable securities | 60,295 | 17,363 |
| Accounts receivable, net | 205,226 | 139,444 |
| Inventories | 32,980 | 26,753 |
| Prepaid expenses and other current assets | 62,914 | 44,070 |
| Total current assets | 1,241,306 | 797,749 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's short-term investments?
- BridgeBio Pharma (BBIO) reported short-term investments of $60.3M in Q1 2026.
- What is the long-term trend for BridgeBio Pharma's short-term investments?
- Over 5 years (2020 to 2025), BridgeBio Pharma's short-term investments has grown at a -41.4% compound annual growth rate (CAGR), from $251.01M to $17.36M.
- What does short-term investments mean?
- Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.
Ask your AI about BridgeBio Pharma's short-term investments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude